Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis.
about
Antibiotic regimens for treatment of infections due to multidrug-resistant Gram-negative pathogens: An evidence-based literature reviewAntimicrobial resistance in Acinetobacter baumannii: From bench to bedsideColistin for lung infection: an updateComparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill PatientsAnticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter InfectionsHow to treat VAP due to MDR pathogens in ICU patients.In vitro and in vivo analysis of antimicrobial agents alone and in combination against multi-drug resistant Acinetobacter baumannii.High prevalence of oxacillinases in clinical multidrug-resistant Acinetobacter baumannii isolates from the Tshwane region, South Africa - an update.Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complexMeta-analysis of colistin for the treatment of Acinetobacter baumannii infectionA prospective evaluation of synergistic effect of sulbactam and tazobactam combination with meropenem or colistin against multidrug resistant Acinetobacter baumannii.In Vitro Synergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant Acinetobacter baumannii.Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii.Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial.Ventilator-Associated Pneumonia (VAP) with Multidrug-Resistant (MDR) Pathogens: Optimal Treatment?Emerging drugs for nosocomial pneumonia.Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis.Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.Multicenter Study of Clinical Features of Breakthrough Acinetobacter Bacteremia during Carbapenem Therapy.Risk factors of multidrug-resistant Acinetobacter baumannii recurrence after successful eradication in ventilated patients.Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis.An antibiotic stewardship exercise in the ICU: building a treatment algorithm for the management of ventilator-associated pneumonia based on local epidemiology and the 2016 Infectious Diseases Society of America/American Thoracic Society guidelines.Is there a future for tigecycline?Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis.Identifying Risk Factors for Healthcare-Associated Infections Caused by Carbapenem-Resistant Acinetobacter baumannii in a Neonatal Intensive Care Unit.The road forward in the management of Acinetobacter infections in the ICU.In vitro assessment of cefoperazone-sulbactam based combination therapy for multidrug-resistant Acinetobacter baumannii isolates in China.Characteristics and Outcomes of Acinetobacter baumannii Infections in Patients with HIV: A Matched Case-Control Study
P2860
Q26796605-598333EB-EC6F-46AE-AB2F-DD640C60B728Q27024893-975768AD-4358-46F3-A5E3-2C02F8423D1FQ28082041-DE9CE6D0-0763-43D1-9E80-F45919D72B5CQ28550492-5E3ABAB4-E01D-4BD8-9311-05C6F0B6657BQ33732524-888333F5-3534-49F2-9B0F-80D910E302F1Q35457068-1D7C1C8E-1207-481F-832D-41E59C6052C6Q35650658-FC55DA6A-4021-424B-8DEB-9AADF6E017C2Q35843094-C48F1B4F-278E-4221-8D58-1BDDCABC3EC1Q36078359-32B20E6C-975E-4DB7-8A8D-8FF5B6BB5961Q36096472-EC674156-3D00-4071-89C5-991124E1490DQ36310173-6A676F80-1A60-40B6-8BBE-FC1CA5736CF4Q36402290-A533094E-EE7F-488E-AE77-1F5B978134C6Q37358693-A8D03498-C777-4418-84A8-147A3AFF253FQ37600495-5310A6E0-1350-47A6-8FE0-4AF730F2A0ADQ38394222-CC3C8145-3DB6-4BFA-8D9C-213055780B39Q38532531-69399563-DCEB-4B7F-BDB9-AA10934A066DQ38878167-E21AF364-0AC8-44B2-BB36-0ECD5BF08070Q38953618-9D1C10FD-F1F9-448E-9268-DB18775C73E6Q39038590-85E151F5-5E6B-4E4B-8C6E-CC64287A05FAQ39167693-C3ACD40C-CC76-4A45-990D-A6923D927C54Q40627684-E1E78078-4BA6-46ED-AFE1-F1A21515BAB0Q43202091-F3ACF239-A9D0-42D5-BE6E-A56B774EBACBQ47143645-7713CB02-D871-4F0D-BD33-638ED19D2D40Q47566277-0F8F50AF-EBDE-480E-9FB8-B11FA41BB16BQ48908629-05AECE8F-FE11-48EE-B06F-76E312DA7029Q50082670-DE6EF7B5-B468-436E-8C20-66B397D54C10Q53692088-B822BFA9-63D0-4B64-B5DC-E19621B7EDF3Q54734722-3C161718-EE4E-4752-B5BC-C2B66B602A32Q55266483-490C57CD-EFDA-4BBD-ABB5-3D0F6BC26F3CQ57799888-DA920792-50C8-452B-9954-5A315C2E41B2
P2860
Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Effectiveness of tigecycline-b ...... ng: a matched cohort analysis.
@ast
Effectiveness of tigecycline-b ...... ng: a matched cohort analysis.
@en
type
label
Effectiveness of tigecycline-b ...... ng: a matched cohort analysis.
@ast
Effectiveness of tigecycline-b ...... ng: a matched cohort analysis.
@en
prefLabel
Effectiveness of tigecycline-b ...... ng: a matched cohort analysis.
@ast
Effectiveness of tigecycline-b ...... ng: a matched cohort analysis.
@en
P2860
P50
P921
P356
P1476
Effectiveness of tigecycline-b ...... ng: a matched cohort analysis.
@en
P2093
Chien-Yu Cheng
P2860
P2888
P356
10.1186/1471-2334-14-102
P577
2014-02-24T00:00:00Z
P5875
P6179
1024120098